Jose-Carlos Gutierrez-Ramos, Ph.D. is Group Senior Vice President and Head of BioTherapeutics Research & Development. This organization is responsible for advancing the research and development of new therapies for inflammatory, rare and immunological diseases, as well as providing industry leading biotechnology science and technology platforms that are leveraged across Pfizer. BioTherapeutics is also home to Pfizer’s Centers for Therapeutic Innovation (CTI).
“Successfully delivering new therapies to patients in today’s evolving healthcare system requires an entirely different way of thinking about collaboration. We are creating new ways of partnering with different players within the R&D ecosystem – academia, government, other biopharma companies, disease foundations – in order to access and advance innovation wherever it may live.”
Senior Vice President and Head, BioTherapeutics Research and Development
Jose-Carlos “JC” Gutierrez-Ramos, Ph.D., is founder of the Centers for Therapeutic Innovation, Senior Vice President and Head of BioTherapeutics Research and Development. He is passionate about the early and iterative use of experimental medicine approaches in discovery research, the continuous focus on scientific innovation and medical differentiation during drug discovery, and the “entrepreneurialization” of big pharma research groups.
Dr. Gutierrez-Ramos also serves as Site Head for the Cambridge, Mass. and Boston, Mass. research laboratories of Pfizer.
Prior to joining Pfizer, Dr. Gutierrez-Ramos was Senior Vice President and Head of the Immuno-Inflammation Center for Drug Discovery at GlaxoSmithKline (GSK). Prior to GSK, he served as Site Head and Chief Scientific Officer at Amgen Mountain View. Previously, he served as Senior Vice President of R&D at Avidia prior to its acquisition by Amgen, where he led a significant research effort in respect of novel protein therapeutics for autoimmune disease. Before his Avidia appointment, he served as Chief Scientific Officer of Peptimmune Inc., where he was responsible for the development of peptide-based therapeutics for autoimmune disease. Before Peptimmune, he served as Vice President of Inflammation at Millennium Pharmaceuticals, where he was responsible for advancing preclinical candidates in inflammation & immunology into human trials.
Dr. Gutierrez-Ramos received his Ph.D. in immunochemistry and master’s degree in chemistry from the Autonoma University of Madrid, Spain. Before coming to the United States, he was a member of the Basel Institute for Immunology in Basel, Switzerland, and a fellow at the Max-Plank Institut für Immunbiologie in Freiburg, Germany. He has co-authored more than 130 peer-reviewed publications and has served on the faculty of Harvard Medical School in the Department of Genetics.